Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has earned a consensus rating of “Moderate Buy” from the twenty-six ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and three have given a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $945.32.

REGN has been the topic of a number of recent analyst reports. The Goldman Sachs Group dropped their price objective on Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a “buy” rating on the stock in a report on Monday, April 14th. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $1,004.00 to $975.00 and set a “buy” rating on the stock in a report on Wednesday, April 23rd. Bank of America lowered their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a report on Thursday, April 17th. Cantor Fitzgerald began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $695.00 price target on the stock. Finally, Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research report on Monday, January 27th.

Regeneron Pharmaceuticals Stock Down 6.9 %

REGN stock opened at $568.91 on Wednesday. Regeneron Pharmaceuticals has a fifty-two week low of $525.99 and a fifty-two week high of $1,211.20. The company’s 50 day moving average price is $633.34 and its 200 day moving average price is $718.04. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The firm has a market capitalization of $62.20 billion, a price-to-earnings ratio of 14.86, a PEG ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $9.55 earnings per share. On average, equities research analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Willner & Heller LLC increased its holdings in Regeneron Pharmaceuticals by 3.9% in the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock valued at $284,000 after purchasing an additional 15 shares in the last quarter. OLD Second National Bank of Aurora boosted its position in shares of Regeneron Pharmaceuticals by 0.5% in the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock worth $2,025,000 after buying an additional 15 shares during the period. Rakuten Securities Inc. boosted its position in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 15 shares during the period. TD Private Client Wealth LLC grew its stake in shares of Regeneron Pharmaceuticals by 9.6% in the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 15 shares in the last quarter. Finally, Manchester Capital Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 12.6% during the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 18 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.